SecBot SecBot
8-K ·Filed Sep 1, 2026

STLN

Starling Oncology, Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed1mo ago SEC0001079973-26-001208
Actionable Insight • Neutral

This is a routine director succession event with no material financial or strategic implications. Monitor for any additional board departures or changes in governance ahead of the 2027 annual meeting, but no near-term trading action is warranted.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+20d
STLN ▲ +3.78% at T+20d
NEUTRAL call +3.78% · α vs SPY +3.86% · entry $6.09 → $6.32
Next anchor: T+60d in 29d
Latest observation: T+36 +11.70% FF3 residual α
Entry = T+0 close
Sep 1, 2026
via day close
T+1d
-1.97%
call -1.97% · α -3.02%
$5.97
settled 8w ago
T+5d
+1.81%
call +1.81% · α +2.76%
$6.20
settled 7w ago
T+20d
+3.78%
call +3.78% · α +3.86%
$6.32
settled 27d ago
T+60d
Pending
in 29d

Price Chart

Loading chart...

Executive Summary

Brad Hively, Vice Chairman of the Board, notified Starling Oncology of his decision not to stand for re-election at the 2027 annual meeting. He will step down immediately from his Vice Chairman and committee roles but remain a director until the meeting. The filing states his decision is not due to any disagreement with the company, making this a routine governance transition with no immediate operational impact.

Key Facts

  • Brad Hively notified the company on September 1, 2026, of his decision not to stand for re-election to the Board at the 2027 annual meeting.
  • Hively will immediately cease serving as Vice Chairman of the Board and as a member of the Compliance Committee and any other committees.
  • Hively is expected to continue serving as a director until the 2027 annual meeting.
  • The filing explicitly states the decision is not the result of any disagreement with the company regarding operations, policies, or practices.

Financial Impact

No financial impact from this director transition.

Risk Factors

  • Potential loss of board expertise or continuity if Hively's departure is not adequately backfilled.
  • Risk of further board departures if this signals broader governance dissatisfaction, though the filing explicitly denies any disagreement.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Offices & Clinics of Doctors of Medicine
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (STLN) — Batch item 10001079973-26-001208
Document: 0001079973-26-001208-index-headers.html0001079973-26-001208
Document: 0001079973-26-001208-index.html0001079973-26-001208
Document: 0001079973-26-001208.txt0001079973-26-001208
8-K Filing (STLN) — Batch item 50001079973-26-001208
Document: 0001079973-26-001208-index-headers.html0001079973-26-001208
Document: 0001079973-26-001208-index.html0001079973-26-001208
Document: 0001079973-26-001208.txt0001079973-26-001208
3 reports for STLN
Performance horizon
Filters
Rows
Reports for STLN — sortable, filterable
TypeNow
Sep 1, 2026
7w ago
8-K
NEUTRAL ★ 2/10
$6.09 $6.32▲ +3.78%▲ +3.86%$6.59 (+8.21%)
Aug 24, 2026
9w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.30 $6.82▲ +8.25%▲ +8.01%$6.59 (+4.60%)
Aug 17, 2026
10w ago
Insider Buy
NEUTRAL ★ 3/10
$6.31 $6.37▲ +0.95%▲ +2.93%$6.59 (+4.44%)
Showing 3 of 3

US Market Status

Market Closed — Opens Wed (15h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026